Company: CERO
Filing Date: 2025-07-21
Form Type: S-1
Source: 0001213900-25-066152
Chunk: 33

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-07-21
Form: S-1
Chunk 33
---
 of our arrangement with Keystone may also make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise wish to effect such sales. We may use proceeds from sales of our Common Stock made pursuant to the Keystone Purchase Agreements in ways with which you may not agree or in ways which may not yield a significant return. We will have broad discretion over the use of proceeds from sales of our Common Stock made pursuant to the Keystone Purchase Agreements, including for any of the purposes described in the section entitled “ Use of Proceeds,” and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. Because of the number and variability of factors that will determine our use of the net proceeds, their ultimate use may vary substantially from their currently intended use. While we expect to use the net proceeds from this offering as set forth in “ Use of Proceeds,” we are not obligated to do so. The failure by us to apply these funds effectively could harm our business, and the net proceeds may be used for corporate purposes that do not increase our operating results or enhance the value of our Common Stock. Risks Related to this Offering by the Selling Securityholder The shares of Common Stock being offered in this prospectus represent a substantial percentage of the outstanding shares of Common Stock, and the sales of such shares, or the perception that these sales could occur, could cause the market price of the Common Stock to decline significantly. Under this prospectus, the Selling Securityholder can resell up to a total of 12,500,000 shares of Common Stock. The shares of Common Stock being offered for resale pursuant to this prospectus by the Selling Securityholder would represent approximately 85.5% of the shares of fully-diluted Common Stock outstanding as of June 30, 2025, assuming and after giving effect to the conversion of all outstanding Preferred Shares, the exercise of all outstanding Warrants and options, and options available for issuance pursuant to our 2024 Plan and 2024 ESPP Plan, as amended from time to time, of which 1,994,227 shares were held by non-affiliates (without taking into account beneficial ownership or stock exchange limitations). Given the substantial number of shares of Common Stock being registered pursuant to this prospectus, the sale of such shares, or the perception in the market of the potential for the sale of a large number of shares, could increase the volatility of the market price of